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deviate from practice guidelines. We compared observed clinical testing and treat-
ment practices to practices that follow guidelines to target adjuvant trastuzumab 
in HER2+ BC using cost-utility analysis. Methods: We used a probabilistic decision 
tree linked to a Markov model to estimate the incremental cost-utility of 2 alterna-
tive test-treat strategies to target adjuvant trastuzumab in Canadian BC patients; 
primary fluorescence in situ hybridization (FISH) vs. primary immunohistochem-
istry (IHC) with FISH confirmation with trastuzumab treatment for all FISH+ or 
IHC+. The BC Markov model was calibrated against Canadian BC registry mortality. 
Population-level observational data informed model probabilities of confirmatory 
FISH testing, probabilities of treatment based on test results, and HER2+ disease 
prevalence under the current practice scenario. Uncertainty was characterized 
using deterministic and probabilistic sensitivity analyses and cost-effectiveness 
acceptability curves (CEACs). Results: In the base case analysis assuming 20% 
HER2+ disease prevalence and perfect adherence to testing and treatment guide-
lines, primary FISH testing was dominant; it decreased costs by a mean of $815 and 
improved outcomes by 0.0022 QALYS compared to the strategy of primary IHC with 
FISH confirmation of equivocal results. Health outcomes were poorer in simula-
tions of current testing and treatment practice. Results were sensitive to HER2+ 
disease prevalence rate, test accuracy, treatment benefit carryover and testing 
behaviors. ConClusions: Improved adherence to treatment guidelines combined 
with primary FISH testing could improve long-term outcomes and costs in practice. 
Local disease epidemiology should be considered when formulating personalized 
medicine policies. Scenario analyis comparisons of guideline adherent vs. practice 
patterns derived from observational data can provide important insights into the 
consequences of deviations from practice when forming policy.
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objeCtives: This research aimed to estimate the standard of resource use 
and its cost associated of treating CML patients, considering hematological 
and non-hematological adverse events grades 3-4 from the perspective of the 
Brazilian National Health System. Cost of treatment per event was generated 
as a result. Methods: A Delphi methodology was applied in Brazil to study the 
management of adverse events related to CML by collecting data on resource 
used and estimating costs associated. Ten experts completed the questionnaires 
developed and the results were compiled and validated. The data collected were 
related to the percentage of patients affected by each AE and to the resource 
used for management. The unit cost of resources was based on the Price Bank 
System (SUS-SIGTAP). Cost of treatment considered treatment options and moni-
toring (e.g., outpatient visits, laboratory tests, procedures, hospitalizations) in 
the Brazilian Public Health System. Results: Among non-hematologic adverse 
events, gastrointestinal bleeding and central nervous system (CNS) hemorrhage 
presented the highest costs of treatment (R$ 1.022,90 and R$ 1.173,34, respectively). 
Hospitalization was the resource with more impact; mainly in CNS hemorrhage, 
with an average length of hospitalization reported by the experts of 1 week and 
also demanded by 100% of patients affected by this AE. Management of cardiac 
events and pericardial effusion was R$973,35 and R$3.896,55. Cytopenias are the 
most commonly events in patients with CML receiving BCR–ABL inhibitors; experts 
suggested use of growth factors in patients with CML receiving TKI therapy. Costs 
associated with the management of hematologic adverse events are: Anemia: 
R$14,93, Thrombocytopenia: R$14,47 and neutropenia: R$211,54. ConClusions: 
Adverse event management in CML patients has important economic impact All 
adverse events related to treatment of CML, with differences in the occurrence 
and intensity should be valued and recorded as contributing to the estimative of 
total cost of treating the disease.
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objeCtives: Examine health care cost and utilization among patients diagnosed 
with metastatic colorectal cancer (mCRC) or Gastrointestinal stromal tumor (GIST) 
prior to being treated with Stivarga® (regorafenib). Methods: Adult patients 
treated with Stivarga from 9/27/12-7/31/13 were identified from a large national US 
claims database. Patients were retained if they were continuously enrolled in the 
health plan for at least 6 months before the initial (index) diagnosis and 1 month 
after the index diagnosis. Patients were required to be diagnosed with mCRC or GIST, 
be 18+ years old, and have non-missing demographic information. Health care cost 
and utilization was examined during 2 time periods; 1) the 6 months immediately 
preceding the index fill (fixed baseline) and 2) the entire variable length period pre-
ceding the index fill (variable baseline). Cancer-related cost and utilization included 
claims with a diagnosis of cancer. Results: 283 patients were treated with Stivarga 
and 235 met all inclusion criteria. Mean age was 61.6 years, 66.4% were female, and 
38.7% were Medicare Advantage patients. Mean length of baseline enrollment was 
4.2 years (median: 3.3 years). In the 6-month baseline period, 41.3% of patients had 
an ER visit and 34.0% had an inpatient stay (IP); 18.7% and 32.8% had a cancer-related 
ER visit and IP stay, respectively. On average, patients had 35.8 ambulatory visits; 
27.8 were cancer-related. Mean 6-month health care cost was $78,771 ($6,559 phar-
macy, $72,212 medical); the majority of medical costs were cancer-related ($68,866). 
Cancer-related ambulatory services and IP stays accounted for $57,814 and $9,713, 
respectively. In the variable baseline, cancer-related medical costs were $314,410 
with $240,544 in ambulatory costs. The cost of all chemotherapy (oral and adminis-
tered) was $168,386. ConClusions: Patients treated with Stivarga incur significant 
health care cost and utilization, accounting for over $18.5 million in health care cost 
in the 6 months prior to initiating Stivarga.
ally. All costs were reported in Egyptian pounds of the financial year 2013. Results: 
The total quality-adjusted life-years (QALYs) of pazopanib was estimated to be 725 
and that for sunitinib was 674, which resulted in a difference of 51 QALYs. The total 
costs for pazopanib and sunitinib were EGP 2,692,116 and EGP 3,712,660, respectively 
(the difference was -1,020,543), which yielded an incremental cost-effectiveness 
ratio of EGP -19,946/QALY. Thus, pazopanib was superior. Various one-way sensi-
tivity analyses indicated that the overall survival medians of both drugs had the 
greatest effects on the results. ConClusions: The present study concludes that, 
from the perspective of the health insurance, pazopanib is more effective and less 
costly than sunitinib for patients with metastatic renal cell carcinoma. This model 
addresses both the health and economic implications of both drugs. These results 
suggest that pazopanib is the superior therapy. This study helps to inform decisions 
about the allocation of health care system resources and to achieve better health 
in the Egyptian population.
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objeCtives: Coffee (Coffea arabica) is one of the most widely consumed beverages 
worldwide. Epidemiologic studies suggest coffee may prevent some chronic diseases 
and cancers. This study aims to assess the cost-utility of coffee consumption from 
a US consumer perspective. Methods: A cohort life-table analysis was developed 
to model life years (LYs) and quality-adjusted life years (QALYs) of coffee drink-
ers versus non-drinkers over a lifetime horizon. Age- and sex-specific incidence 
and mortality rates were used to model outcomes of chronic disease (Alzheimer’s, 
depression/suicide, diabetes, heart failure, Parkinson’s, stroke) and cancer (blad-
der, breast, colorectal, endometrial, esophageal, leukemia, liver, oral, pancreatic, 
prostate). Relative risks of chronic diseases and cancers by cups of coffee consumed 
daily were obtained from meta-analyses of prospective cohort and case-control 
studies. Utility weights, baseline health care costs, and attributable disease costs 
were obtained from the literature. Costs per cup of coffee were estimated for home 
preparation and obtained from a national sample of low- and high-cost vendors. 
Incremental analyses were conducted by dose, cost, and sex. The model was vali-
dated by comparing predicted life-expectancy to data from studies examining all-
cause mortality of coffee consumption. Probabilistic sensitivity analyses (PSA) were 
conducted. Results: Coffee increased undiscounted LYs in 2, 4, and 6 cup/day male 
(0.29, 0.52, 0.70) and female (0.31, 0.54, 0.69) drinkers, respectively, compared to 
non-drinkers. Home preparation resulted in ICERs per discounted QALY of $36,031, 
$44,125, and $55,572 for male and $31,029, $37,779, and $46,280 for female drink-
ers, respectively, for 2, 4, and 6 cups/day. ICERs were higher for coffee purchased 
from low-cost vendors (> $50,000/QALY) and high-cost vendors (> $80,000/QALY). 
In the PSA, 4 and 6 cups/day were most likely cost-effective for males and females, 
respectively, at a $50,000/QALY threshold. ConClusions: Coffee consumption may 
be a cost-effective approach to improve health outcomes. Given the limitations of 
observational effectiveness data, additional research is warranted.
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objeCtives: Compare demographic and clinical characteristics among colorectal 
cancer (CRC) patients with different treatment lines (TL) in the U.S. veteran popula-
tion. Methods: Adult patients with at least one administration of CRC treatment 
were selected from the U.S. Veterans Health Administration database (01APR2006-
30SEP2012). The first observed treatment date was designated as the index date. 
Patients were required to have continuous pharmacy and medical benefits at least 
6 months pre-index date (baseline) and were followed until the earliest of death, 
or end of enrollment or study period. At least one primary CRC diagnosis code was 
required during the baseline period. Four cohorts were created based on the number 
of TL. Demographic and clinical characteristics were compared among patients with 
one, two, three, or four TL using appropriate statistical tests. Results: A total of 
11,078 patients were included in the study sample (63% with one TL; 22% with two 
TL; 8% with three TL; 7% with four TL). Patients treated with three or four TL were 
similar in age (3 TL: 63.8 years; 4 TL: 63.3) but significantly younger compared to 
patients with one or two lines (1 TL: 67.0; 2 TL: 64.6). Patients with 3 or 4 TL had a 
lower Chronic Disease Score, and lower rates of hypertension and stroke. During the 
6-month baseline period, patients with 1 TL had much longer hospitalization stays 
and a higher rate of inpatient visits (7.3 days, 57.4%) compared to patients in other 
cohorts. A similar trend was found in baseline health care costs, where patients 
with 1 TL incurred the highest costs ($38,010) compared to the other three cohorts 
(2 TL: $34,332; 3 TL: $33,738; 4 TL: $31,120; all p-values< 0.002). ConClusions: CRC 
patients with more than two TL were younger and had less comorbid conditions 
than patients with one or two TL.
PCN134
Cost-utility aNalysis of PRaCtiCe deviatioNs fRom guideliNes iN 
heR2-taRgeted testiNg aNd tReatmeNt foR BReast CaNCeR
Ferrusi I.L.1, Kulin N.A.2, Goeree R.1, Leighl N.3, Pullenayegum E.M.4, Phillips K.5, Marshall D.2
1McMaster University, Hamilton, ON, Canada, 2University of Calgary, Calgary, AB, Canada, 
3Ontario Cancer Institute, Toronto, ON, Canada, 4Hospital for Sick Children, Toronto, ON, Canada, 
5University of California, San Francisco, San Francisco, CA, USA
objeCtives: Observational research suggests that personalized medicine practices 
in human epidermal growth factor receptor-2 positive (HER2+) breast cancer (BC) 
